Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-02-06
2004-11-23
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S155000, C546S157000, C546S158000, C514S312000, C514S314000
Reexamination Certificate
active
06822097
ABSTRACT:
FIELD OF THE INVENTION
This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cell proliferation-related disorders, cell death and apoptosis-related disorders.
BACKGROUND OF THE INVENTION
Identification of therapeutic agents effective in the treatment of neoplastic diseases or for the treatment of neurological disorders is the subject of significant research efforts.
Protein kinases represent a large family of proteins which play a central role in the regulation of a wide variety of cellular processes and maintaining control over cellular function. A partial list of such kinases includes ab1, Akt, bcr-ab1, B1k, Brk, Btk, c-kit, c-met, c-src, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, cRaf1, CSF1R, CSK, EGFR, ErbB2, ErbB3, ErbB4, Erk, Fak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, FLK-4, flt-1, Fps, Frk, Fyn, Hck, IGF-1R, INS-R, Jak, KDR, Lck, Lyn, MEK, p38, PDCFR, PIK, PKC, PYK2, ros, tie, tie2, TRK, Yes, and Zap70. As such, inhibition of kinases has become an important therapeutic target.
Cell proliferation is the rapid reproduction of cells, such as by cell division. The cell cycle, which controls cell proliferation, is itself controlled by a family of serine-threonine kinases called cyclin dependent kinases (CDKs). The regulation of CDK activation is complex, and requires the association of the CDK with a member of the cyclin family of regulatory subunits. A further level of regulation occurs through both activating and inactivating phosphorylations of the CDK subunit. The coordinate activation and inactivation of different cyclin/CDK complexes is necessary for normal progression through the cell cycle. Both the critical G1-S and G2-M transitions are controlled by the activation of different cyclin/CDK activities. Loss of control of CDK regulation is a frequent event in hyperproliferative diseases and cancer. (T. Noguchi et al., Am. J. Pathol., 156, 2135-47 (2000)) As such, inhibition of CDKs has become an important target in the study of chemotherapeutics (A. Senderowicz and E. Sausville, J. Nat. Canc. Instit., 92, 376-87 (2000)).
Kinases have also been implicated in diseases and disorders of the central nervous system. For example, patients suffering from stroke, Alzheimer's disease or Parkinson's disease would benefit from the inhibition of kinases. Cdk5 has been shown to be involved in Alzheimer's pathology (R. Maccioni, et al., Eur. J. Biochem., 268, 1518-27 (2001)) and with neuronal development (G. Paglini and A. Caceres, Eur. J. Biochem., 268, 1528-33 (2001)).
Protein kinases also control programmed cell death, also known as apoptosis. Apoptosis is a ubiquitous physiological process used to eliminate damaged or unwanted cells in multicellular organisms. Disregulation of apoptosis is believed to be involved in the pathogenesis of many human diseases. The failure of apoptotic cell death has been implicated in various cancers, as well as autoimmune disorders. Conversely, increased apoptosis is associated with a variety of diseases involving cell loss such as neurodegenerative disorders and AIDS. As such, inhibition of apoptosis has become an important therapeutic target. Cdk5 has been shown to be involved in apoptosis pathology (A. Catania et al., Neuro-Oncology, 89-98 (April 2001)).
Quinolinones are known in the art. U.S. Pat. No. 4,127,574, issued Nov. 28, 1978, describes 3-sulfonyl-quinolinones as anti-allergic agents. U.S. Pat. No. 4,547,511, issued Oct. 15, 1985, describes 3-carboxamide-quinolinones as pharmaceuticals. S. Ibrahim et al., Ind. J. Het. Chem., 4, 125-130 (1994) describe 1-methylquinolinones. A. Sayed et al., Acta Chim. Acad. Sci. Hung., 94, 131-39 (1977), describes the preparation of 1-alkylquinolinones. M. Abass, Synth. Commun., 30, 2735-57 (2000), describes the preparation of 1-methylquinolinones. WO01/70227, published 27 Sep. 2001, describes 3-heterocyclylquinolinones as GnRH antagonists. WO01/70228, published 27 Sep. 2001, describes 3-phenylquinolinones as GnRH antagonists. WO01/62252, published 30 Aug. 2001, describes 3-pyrrolopyridinyl-quinolinones as tyrosine kinase inhibitors. WO01/29025, published 26 Apr. 2001, describes 3-(2-indolyl)quinolinones as tyrosine kinase inhibitors.
U.S. Pat. No. 5,252,584, issued Oct. 12, 1993, describes 4-hydroxy-quinolinones as NMDA antagonists. K. Ashok et al., Ind. J. Chem., 32B, 786-87 (1993), describe the preparation of 4-hydroxy-quinolinones. E. Mohamed et al., J. Ind. Chem. Soc, 69, 82-4 (1992), describe the preparation of 4-hydroxy-quinolinones. WO92/18483, published 29 Oct. 1992, describes 1-methyl-4-hydroxy-quinolinones as pharmaceuticals. WO01/28993, published 26 Apr. 2001, describes 6-(indazol-2-yl)-thieno[2,3-b]pyridones as kinase inhibitors. M. Rehwald et al., J. Prakt. Chem., 342, 371-78 (2000), describe preparation of heteroaryl pyridinium salts. G. Tenant et al., J. Chem. Soc., Perkin Trans. 1, 827-32 (1999), describe preparation of heterocyclyl-pyridinium salts. K. Gewald et al., Liebigs Ann., 787-91 (1995), describe preparation of heterocyclyl-pyridinium salts. T. El-Emary et al., Pharmazie, 55, 356-58 (2000), describe the preparation of pyrazolo[3,4-b]pyridin-2-ones. S. Naruto, et al., Chem. Pharm. Bull., 30, 3421-23 (1982), describe the preparation of benzofuro[3,2-b]pyridin-2-ones. WO01/62251, published 30 Aug. 2001, describes 3-pyrrolopyridinyl-quinolinones as tyrosine kinase inhibitors. WO01/29025, published 26 Apr. 2001, describes 3-(2-indolyl)quinolinones as tyrosine kinase inhibitors. WO01/28993, published 26 Apr. 2001, describes 3-(2-benzimidazolyl)quinolinones as tyrosine kinase inhibitors. WO01/62252, published 30 Aug. 2001, describes 3-pyrrolopyridinyl-quinolinones. U.S. Pat. No. 5,643,932, issued Jul. 1, 1997, describes thiazoles as superoxide radical inhibitors. A. Doroshenko et al. Chem. Heterocycl. Cmpd., 33, 1177-84 (1998) describes spectral properties of thiazolyl-coumarin derivatives.
However, compounds of the current invention have not been described as inhibitors of cell proliferation or apoptosis such as for the treatment of cancer or stroke.
REFERENCES:
patent: 4127574 (1978-11-01), Hardtmann et al.
patent: 4547511 (1985-10-01), Eriksoo et al.
patent: 5252584 (1993-10-01), Carling et al.
patent: 5480883 (1996-01-01), Spada et al.
patent: 5643932 (1997-07-01), Chihiro et al.
patent: 5945422 (1999-08-01), Doherty et al.
patent: 6605617 (2003-08-01), Renhowe et al.
patent: 1295883 (2003-03-01), None
patent: WO 92/18483 (1992-10-01), None
patent: WO 96/22990 (1996-08-01), None
patent: WO 96/34867 (1996-11-01), None
patent: WO 99/09030 (1999-02-01), None
patent: WO 01/28993 (2001-04-01), None
patent: WO 01/29025 (2001-04-01), None
patent: WO 01/62251 (2001-08-01), None
patent: WO 01/62252 (2001-08-01), None
patent: WO 01/70227 (2001-09-01), None
patent: WO 01/70228 (2001-09-01), None
patent: WO 01/98300 (2001-12-01), None
M. Abass, “Chemistry of Substituted Quinolinones, Part II Synthesis of Novel 4-Pyrazolylquinolinone Derivatives”, Synthetic Communications, 30(15): 2735-2757 (2000).
K. Ashok et al., “Synthesis of 1-aryl-4-ethoxypyrazolo-[4,3-c]quinolines and 3-(3-arylisoxazol-5-yl)-2/4-hydroxyquinolin-2/4-ones: Revision of the reported wrong structures”, Indian Journal of Chemistry, 32B: 786-787 (1993).
A. Catania et al., “Expression and localization of cyclin-dependent kinase 5 in apoptotic human glioma cells”, Neuro-Oncology, 89-98 (2001).
A. Doroshenko et al., “Physical Properties and Theoretical Considerations”, Chem. Heterocycl. Compd., 33:1177-1184 (1998).
T. El-Emary et al., “New polycylic azines derived from pyrazolo[3,4-b]pyridine”, Pharmazie, 55:356-358 (2000).
K. Gewald et al., Synthesis of New Substituted 1-(3-Pyridyl)pyridinium Salts and 3,4-Diamino-2(1H)-pyridinones, Liebigs Ann., 787-791 (1995).
S. Ibrahim, “Synthesis of Some Heterocyclic Rings as Substituents to Quinolone Moiety”, Indian Journal of Heterocyclic Chemistry, 4:125-130 (1994).
R. Maccioni et al., “The protein kinase Cdk5: Stru
Kaller Matthew
Liu Hu
Nguyen Thomas
Norman Mark H.
Rzasa Robert
Amgen Inc.
Seaman D. Margaret
LandOfFree
Compounds and methods of uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods of uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods of uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3323418